Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5Endocrine 2NET 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 208Carcinoid Tumor 26Neoplasms 22Pancreatic Neoplasms 16Gastro-enteropancreatic neuroendocrine tumor 14Carcinoma, Neuroendocrine 11Carcinoma 11Adenoma, Islet Cell 11Neoplasm Metastasis 10Colorectal Neoplasms 9Lung Neoplasms 8Serotonin Syndrome 7Prostatic Neoplasms 7Adenocarcinoma 7Pheochromocytoma 6Gastrointestinal Neoplasms 6Colonic Neoplasms 6Breast Neoplasms 6Thyroid Neoplasms 5Stomach Neoplasms 5Somatostatinoma 5Neuroblastoma 5Melanoma 5Gastroenteropancreatic Neuroendocrine Tumors 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Vipoma 4Sarcoma 4Rectal Neoplasms 4Paraganglioma 4

Interventions

gallium Ga 68 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × von Hippel-Lindau Disease × NET × Clear all
NCT01967537 2019-11-19

Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
341 enrolled 14 charts
EndocrineNET

von Hippel-Lindau Disease, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡